Diabetes Mellitus Type 2 Clinical Trial
— GLPNCT number | NCT00473733 |
Other study ID # | 65/07 |
Secondary ID | |
Status | Not yet recruiting |
Phase | Phase 4 |
First received | May 13, 2007 |
Last updated | May 14, 2007 |
Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like
peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal
tract. These hormones are secreted after meals and have some roles in regulating the
digestion process, absorption, and sending signals to the brain that regulate food
consumption. GLP peptides affect peripheral targets and have an important homeostatic role.
GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable
adequate intestine growth.
We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different
zones of the stomach in diabetes type 2 patients. If there are differences, it might explain
the pathological gastric emptying in these patients.
Understanding the function of these peptides may lead to new therapeutic options for
diabetic patients with delayed gastric emptying.
Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be
included in the study and 20 controls aged 18-70 years. Patients with neurological disease
will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the
antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP
receptors expression will established by real time PCR method. Patients with different
expression compared to control will undergo isotopic scan for gastric emptying.
Status | Not yet recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years Exclusion Criteria: - Patients with neurological disease will be excluded |
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Israel | Assaf Harofeh Medical Center | Zerifin |
Lead Sponsor | Collaborator |
---|---|
Assaf-Harofeh Medical Center |
Israel,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01267448 -
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
|
Phase 4 | |
Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Terminated |
NCT02373865 -
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 | |
Completed |
NCT01305434 -
Mulberry Leaf Extract and Blood Glucose Control in Diabetics
|
Phase 1/Phase 2 | |
Completed |
NCT01330121 -
Bridging the Gap by Transitional Care
|
N/A | |
Recruiting |
NCT00992797 -
Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity
|
Phase 2 | |
Completed |
NCT01580904 -
Impact of Pharmaceutical Care in Diabetics Patients
|
N/A | |
Active, not recruiting |
NCT00728403 -
Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00763815 -
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
|
Phase 3 | |
Active, not recruiting |
NCT00529815 -
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00517465 -
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
|
Phase 1 | |
Completed |
NCT00119041 -
Diabetes Telemedicine Consultation: A Systems Improvement Intervention
|
N/A | |
Withdrawn |
NCT00417716 -
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
|
Phase 3 | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Active, not recruiting |
NCT05887635 -
Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus
|
N/A | |
Completed |
NCT03903965 -
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
|
||
Completed |
NCT02666924 -
Cooking Classes for Chinese Canadian Patients Living With Diabetes
|
N/A | |
Recruiting |
NCT02501850 -
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
|
Phase 4 |